Endo International has completed the acquisition of Auxilium Pharmaceuticals in a transaction valued at $2.6 billion. The closing of the transaction, which was announced Oct. 9, 2014, follows approval by Auxilium's shareholders on Jan. 27 and the receipt of all required regulatory approvals.

The combined company will provide an expanded platform to accelerate the evolution and growth of Endo's U.S. branded pharmaceuticals business. With the acquisition complete, Endo's portfolio has a broader offering of urology and orthopedic products, including Xiaflex, Testopel and Stendra, natural complements to its men's health and pain products.